Lennox-Gastaut syndromeNews & Research
15 curated articles for Lennox-Gastaut syndrome — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Epileptic disorders : international epilepsy journal with videotape Apr 16, 2026
A temporary spike: Investigating Lennox-Gastaut syndrome incidence in the US following FDA approval of cannabidiol.
In June 2018, the US Food and Drug Administration (FDA) approved pharmaceutical grade cannabidiol (CBD; Epidiolex®) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). We sought to examine whether the FDA approval of CBD was associated with changes in LGS diagnostic pra...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Seizure Apr 14, 2026
Soticlestat for drug-resistant epilepsy: Current evidence and clinical perspectives.
Epilepsy, particularly drug-resistant epilepsy, remains a significant clinical challenge, with many patients failing to achieve seizure control through conventional antiseizure medications. This unmet need has directed research toward alternative therapeutic targets, including neurosteroid modulatio...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Seminars in pediatric neurology Apr 10, 2026
EEG findings in Lennox-Gastaut syndrome: Pursuing a moving target.
Lennox-Gastaut Syndrome (LGS) is a life-long, drug-resistant developmental epileptic encephalopathy (DEE) that develops in young children between 18 and 24 months of age and up to 18 years of age. The overall incidence is estimated at 0.1 to 0.28 per 100,000 people per year and a lifetime prevalence...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Neuromodulation : journal of the International Neuromodulation Society Apr 8, 2026
Systematic Review and Meta-Analysis of Bilateral Centromedian Nucleus Neuromodulation for Multifocal and Generalized Epilepsy.
Generalized and multifocal forms of drug-resistant epilepsy are highly prevalent but have limited treatment options. Centromedian nucleus (CMN) thalamic neuromodulation has emerged as an effective treatment for these epilepsies, but head-to-head neuromodulation modality trials do not exist, and opti...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Neuromodulation : journal of the International Neuromodulation Society Apr 8, 2026
Invasive Neuromodulation in Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.
Lennox-Gastaut syndrome (LGS) is a highly drug-resistant epileptic encephalopathy. The high seizure burden in LGS contributes to substantial morbidity, reduced quality of life, and increased mortality, underscoring the need for alternative therapeutic strategies such as invasive neuromodulation. We ...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Epilepsia Apr 7, 2026
Charlotte Dravet: Life and contributions to epileptology.
Charlotte Dravet: Life and contributions to epileptology.
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Epilepsia Mar 27, 2026
A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome.
There remains a need for new treatments for Lennox-Gastaut syndrome (LGS), a developmental and epileptic encephalopathy with a heterogenous patient population that often requires polytherapy. The phase 3, randomized SKYWAY study (NCT04938427) investigated the efficacy and safety of the cholesterol 2...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Epilepsia Mar 26, 2026
Underutilization of syndrome-specific ICD-10 codes for genetic epilepsies: Implications for precision medicine
Published in Epilepsia. Moura Coelho da Silva É et al.
Why it matters: Recent peer-reviewed research relevant to rare disease diagnosis or treatment.
- Acta neurologica Belgica Mar 12, 2026
Biallelic RNU2-2-related neurodevelopmental disorder presenting as Lennox-Gastaut syndrome.
Biallelic RNU2-2-related neurodevelopmental disorder presenting as Lennox-Gastaut syndrome.
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Pharmaceuticals (Basel, Switzerland) Feb 27, 2026
Cannabidiol in Neurology: Current Insights and Translational Perspectives.
Cannabidiol (CBD) is one of the most studied compounds of Cannabis sativa and has attracted significant interest due to its therapeutic and beneficial properties, which have been confirmed in numerous preclinical and clinical studies over the last few years. A great advantage of CBD over the other w...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Epilepsia Feb 23, 2026
Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC).
This randomized, double-blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs). Eligible participants had a D...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Epilepsia Feb 23, 2026
Lennox-Gastaut syndrome unveiled: Advancing diagnosis, therapies, and advocacy-insights from the Genoa International Workshop.
Lennox-Gastaut syndrome (LGS) is one of the most severe, yet one of the most discussed, childhood-onset developmental and epileptic encephalopathies (DEEs). Dissent among epileptologists on the definition and minimum set of electroclinical features derives from the high etiological heterogeneity wit...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Epilepsy & behavior : E&B Feb 14, 2026
Biomarker discovery in Lennox-Gastaut syndrome: Advances and challenges in electrophysiological, genetic, neuroimaging, and neuroinflammatory approaches.
In Lennox-Gastaut Syndrome (LGS), a severe developmental and epileptic encephalopathy, the absence of validated biomarkers limits our ability to detect disease early, predict outcomes, and guide treatment strategies. This review synthesizes advances in biomarker research spanning electrophysiologica...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- International journal of molecular sciences Feb 13, 2026
Unraveling Lennox-Gastaut Syndrome: From Molecular Pathogenesis to Precision Diagnosis and Targeted Therapy Evolving Therapeutic Strategies.
Lennox-Gastaut syndrome (LGS) is a rare and severe developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, mandatory tonic seizures, cognitive and behavioral impairment, and distinctive electroencephalographic features, including slow spike-wave discharges ...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
- Epilepsy research Feb 6, 2026
A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Changes in seizure frequency and adverse events.
The efficacy and safety of a highly purified plant-derived cannabidiol (CBD) oral solution (Epidiolex® [US]/Epidyolex® [EU], EPX) have been established for the treatment of seizures in patients with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. These conditions i...
Why it matters: Recent peer-reviewed research on Lennox-Gastaut syndrome that may be relevant for patients and caregivers.
More on Lennox-Gastaut syndrome
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.